Amgen | AMGN - Betriebsergebnis





Betriebsergebnis Veränderung Datum
AbbVie USD 6.88B 156M 2026-09
Agios Pharmaceuticals USD -110.55M 527K 2026-06
ALKERMES USD 36.59M 102.52M 2026-09
Amgen USD 4.68B 65M 2026-09
Biogen USD 419.5M 663.3M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 268.42M 20.01M 2026-09
Genmab DKK 407M 182M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.86B 251M 2026-09
Glaxosmithkline GBP 2.13B 166M 2026-09
Incyte USD -707.47M 1.41B 2026-09
Ionis Pharmaceuticals USD -130M 27.71M 2026-09
J&J USD 6.47B 1B 2026-09
Merck USD 7.33B 6.49B 2026-09
Moderna USD 130M 945M 2026-09
Neurocrine Biosciences USD 343M 123.1M 2026-09
Novartis USD 5.14B 392M 2026-09
Novartis USD 1.84B 2.39B 2026-09
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 148.98M 103.09M 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 4.72B 2.34B 2026-09
Sarepta Therapeutics USD -9.04M 22.33M 2026-09
Takeda JPY 205.32B 3.9B 2026-09
Teva Pharmaceutical Industries USD 1.19B 954M 2026-09
Ultragenyx Pharmaceutical USD -110M 35M 2026-09
Vertex Pharmaceuticals USD 1.26B 11.3M 2026-09